Results 31 to 40 of about 10,848 (199)

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BMC Cancer, 2022
Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier, Ivan Landego, Oliver Bucher, Mandy Squires, Erin Streu, Irena Hibbert, Theresa Whiteside, Spencer B. Gibson, Marc Geirnaert, James B. Johnston, David E. Dawe, Versha Banerji   +11 more
doaj   +1 more source

Persistent Coronavirus Disease 2019 (COVID-19) in Patients With Malignant Lymphoma Treated With Anti-CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases. [PDF]

Respirol Case Rep
Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19). We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Switching to an antiviral
Horie M, Okimoto T, Okada Y, Inoue M, Shimizu S, Tsuda H, Hata K, Okuno T, Amano Y, Nakao M, Nakashima K, Hamaguchi M, Isobe T.   +12 more
europepmc   +2 more sources

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab [PDF]

, 2022
OBJECTIVE: Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and
Vital, EM, Arnold, J, Hewins, P, Dass, S, Rhodes, B, Twigg, S, Chakravorty, M, Jones, CH, Ehrenstein, M, Md Yusof, MY, Courtney, P   +10 more
core   +3 more sources

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Pharmacogenomics and Personalized Medicine, 2014
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj   +1 more source

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases, 2021
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell ...
R. Furie, G. Aroca, M. Cascino, J. Garg, B. Rovin, A. Álvarez, H. Fragoso-Loyo, Elizabeth Zuta-Santillan, T. Schindler, P. Brunetta, C. Looney, I. Hassan, A. Malvar   +12 more
semanticscholar   +1 more source

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

Haematologica, 2017
The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance therapy with obinutuzumab alone, in previously untreated patients with follicular lymphoma.
Andrew Grigg, Martin J.S. Dyer, Marcos González Díaz, Martin Dreyling, Simon Rule, Guiyuan Lei, Andrea Knapp, Elisabeth Wassner-Fritsch, Paula Marlton   +8 more
doaj   +1 more source

Obinutuzumab as treatment for ANCA-associated vasculitis

, 2021
International audienceAbstract Objectives Rituximab is a standard of care therapy for patients with ANCA-associated vasculitis. When rituximab is contraindicated, or in the case of refractory disease, other treatments are needed.
Langford, Carol, Amudala, Naomi, Sheridan, Brittany, Geara, Abdallah, Merkel, Peter, Cornec, Divi, Boukhlal, Sara, Brittany Sheridan, Carol A Langford, Peter A Merkel, Sara Boukhlal, Naomi A Amudala, Abdallah Geara, Divi Cornec   +13 more
core   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia. [PDF]

Eur J Haematol
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Gao L, Nguyen D, White V, Livingston PM, Cheah CY.   +4 more
europepmc   +2 more sources

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Frontiers in Pharmacology, 2023
Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A ...
Annamaria Mascolo, Annamaria Mascolo, Raffaella Di Napoli, Raffaella Di Napoli, Nunzia Balzano, Nunzia Balzano, Elena D’Alessio, Imma Izzo, Imma Izzo, Francesco Rossi, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano, Annalisa Capuano, Liberata Sportiello, Liberata Sportiello   +15 more
doaj   +1 more source

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both,
C. Niemann, T. Munir, Carol Moreno, Carolyn Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, Tadeusz Robak, M. Šimkovič, Sergey Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, A. Kater   +23 more
semanticscholar   +1 more source